Sector Imager 6000 Plate Reader

描述(由申请人提供)：以下购买Sector Imager 6000电化学发光平板阅读器的提案旨在开发一种高通量共享设施，用于分析自身免疫性疾病的免疫生物标记物，特别是在人类1型自身免疫性糖尿病的诊断和发病机制中发挥作用的自身抗体和细胞因子。该仪器将存放在芭芭拉·戴维斯儿童糖尿病中心，它是世界上六个参考实验室之一，用于分析新诊断患者的自身抗体，并识别自身抗体阳性的有患病风险的个人。后者已被纳入许多国家和国际的转化性研究，遵循疾病的自然历史(DPT-1，TrialNet)和实验性疗法的试验(最近的MMF，利妥昔单抗，贝希尔)。Sector(R)Imager 6000非常适合多用户、多分析格式，无需校准、重置仪器参数，而且与目前许多分析中使用的闪烁计数器和流式细胞仪等仪器相比，使用起来非常方便。现在可以通过使用自身抗体检测结合遗传分析来从普通人群中识别有患病风险的个人，然而，为了实现这一目标，需要使用不使用放射性同位素但可以提供定量数据的新格式来实施自身抗体检测，这些数据可以在世界各地非常不同的操作环境中的多个实验室复制。我们认为，MSD技术是一个很好的选择，因为它将我们带入了技术的前沿，同时提供了一个多功能的平台，可以用于新的分析方法的研究和开发，同时将可移植到最终可能用作服务点分析的全自动化芯片实验室分析中。与辐射和光度技术相比，电化学发光检测在速度、信噪比和较宽的动态范围方面具有明显的优势。在预置的平板上每孔多重分析多达10个分析物的能力大大节省了试剂和操作员的时间。以下建议确定了一组参与翻译研究和常规分析性能的4个主要用户(70%的仪器使用)和7个次要用户(30%的仪器使用)，他们将主要将机器用于动物模型的实验研究和疾病新生物标记物的研究和开发。NIH资助的20笔赠款的支持被记录在案，范围从几个多中心财团到DERC试点和可行性赠款持有者。提供了仪器的管理和维护计划。检测的验证和质量控制将通过我们现有的糖尿病自身免疫标准化计划执行，该计划由疾病控制中心通过糖尿病免疫学会运行。

DESCRIPTION (provided by applicant): The following proposal for the purchase of a Sector Imager 6000 Electrochemiluminescence plate reader is directed towards developing a high throughput shared facility for the analysis of immunological biomarkers of autoimmune disease and in particular autoantibodies and cytokines that play a role in the diagnosis and pathogenesis of type 1 autoimmune diabetes in humans. The Barbara Davis Center for Childhood Diabetes, where the instrument will be housed, is one of six reference laboratories in the world for the analysis of autoantibodies in new-diagnosed patients and for the identification of autoantibody positive individuals at risk of developing disease. The latter have been recruited into numerous national and international translational research studies following the natural history of the disease (DPT-1, TrialNet) and trails of experimental therapies (recently MMF, Rituximab, Bayhill). The SECTOR(R) Imager 6000 is extremely adaptable to a multiuser, multi-assay format without the need for calibration, resetting instrument parameters as well as being easily accessible compared to instruments such as scintillation counters and flow cytometers that are used in many of the current assays. It is now possible through the use of autoantibody testing combined with genetic analysis to identify individuals at risk of developing the disease from the general population however to achieve this goal there is a need to implement autoantibody assays using new formats that do not use radioisotopes yet can provide quantitative data that can be reproduced in multiple laboratories in very different operating environments all over the world. The MSD technology we contend is an excellent choice in that it brings us to the forefront of technology, yet provides a platform that is versatile and can be used for research and development of new assays and at the same time will be transplantable to fully-automated lab-on-a-chip assays that might ultimately be used as a point of service assay. Electrochemiluminescence detection affords distinct advantages in terms of speed, signal to noise and wide dynamic range over radiometric and photometric technologies. The ability to multiplex up to 10 analytes per well on prespotted plates is a significant saving in terms of reagents and operator time. The following proposal identifies a group of 4 major users involved in translational research and routine assay performance (70% instrument use) and 7 minor users (30% instrument use) who will principally use the machine for experimental research in animal models and in the research and development of new biomarkers of disease. Support from 20 NIH funded grants is documented ranging from several multicenter consortia to DERC pilot and feasibility grant holders. A plan for management and maintenance of the instrument is provided. Validation and quality control of the assays will be performed through our existing participation in the Diabetes Autoimmunity Standardization Program run from the Center of Disease control through the Immunology of Diabetes Society.